AstraZeneca’s Durvalumab gets CDSCO nod to treat locally advanced or metastatic biliary tract cancer Read more
USFDA accepts AstraZeneca’s BLA for nirsevimab to prevent RSV lower respiratory tract disease Read more
CDSCO approves AstraZeneca’s Dapagliflozin with additional indication for treating CKD and heart failure patients Read more